| abstract |
This invention is directed to physiologically active compounds of formula (Ib)n nwherein n R 1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z 1 represents a direct bond R 1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; nR 2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, heterocycloalkyl, hydroxy, -SO 2 NR 4 R 5 , -NR 4 SO 2 R 5 , -NR 4 R 5 , -C(=O)R 5 , -C(=O)C(=O)R 5 , -C(=O)NR 4 R 5 , -C(=O)OR 5 , -O(C=O)NR 4 R 5 , or -NR 4 C(=O)R 5 ; nR 3 represents -C(=Z)-N(R 7 )R 6 , -C(=Z)-CHR 12 R 6 , -C(=Z)-R 6 , -CR 8 =C(R 9 )(CH 2 ) p -R 6 , -C(R 10 )=C(R 11 )R 12 , -C(R 13 )(R 10 )C(R 11 )(R 14 )R 12 , -C(R 8 )(R 15 )CH(R 9 )(CH 2 ) p -R 6 , -R 6 , -N(R 16 )C(=Z)R 6 , -C(R 17 )=N-OC(=0)R 18 , -C(=O)-N(R 19 )OR 20 , -C≡C-R 6 , -CH 2 -C(=Z)-R 6 , -C(=Z)-C(=Z)R 6 , -CH 2 -NHR 6 , -CH 2 -ZR 6 , -CH 2 -SOR 6 , -CH 2 -SO 2 R 6 , -CF 2 -OR 6 , -NH-CH 2 R 6 , -Z-CH 2 R 6 , -SO-CH 2 R 6 , -SO 2 -CH 2 R 6 , -O-CF 2 R 6 , -O-C(=Z)R 6 , -N=N-R 6 , -NH-SO 2 R 6 , -SO 2 -NR 21 R 22 , -CZ-CZ-NHR 6 , -NH-CO-OR 6 , -O-CO-NHR 6 , -NH-CO-NHR 6 , -R 23 , -CX 1 =CX 2 R 6 , -C(=NOR 24 ), -(CH 2 ) q R 6 , -CH 2 -CO-NH(CH 2 ) q R 6 , -CH 2 -NH-CO(CH 2 ) q R 6 , -CH 2 -CO-CH 2 R 6 , -C(=NR 25 )-NH(CH 2 ) q R 6 , -C(X 3 )=N-(CH 2 ) q R 6 or -CH(X 4 )-CH 2 R 6 ; nA 1 represents a direct bond, or a straight or branched C 1 - 6 alkylene chain optionally substituted by hydroxyl, alkoxy, oxo, cycloalkyl, aryl or heteroaryl, or A 1 represents a straight or branched C 2 - 6 alkenylene or C 2 - 6 alkynylene chain; nZ 1 represents a direct bond, an oxygen or sulphur atom or NH ; nQ represents a CH linkage or a nitrogen atom; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (Ib) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (Ib), their pharmaceutical use and methods for their preparation. |